Takeda Pharmaceutical Company Limited (TYO:4502)
4,234.00
-46.00 (-1.07%)
May 9, 2025, 3:30 PM JST
TYO:4502 Revenue
In the fiscal year ending March 31, 2025, Takeda Pharmaceutical Company had annual revenue of 4.58T JPY with 7.45% growth. Takeda Pharmaceutical Company had revenue of 1.05T in the quarter ending March 31, 2025, with 0.24% growth.
Revenue
4,581.55B
Revenue Growth
+7.45%
P/S Ratio
1.41
Revenue / Employee
92.97M
Employees
49,281
Market Cap
6,469.33B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 4,581.55B | 317.79B | 7.45% |
Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,222.12B |
Daiichi Sankyo Company | 1,886.26B |
HOYA Corporation | 869.37B |
Terumo | 1,011.15B |
Otsuka Holdings | 2,393.18B |
Astellas Pharma | 1,912.32B |
Olympus | 993.33B |
Shionogi & | 456.87B |
Takeda Pharmaceutical Company News
- 5 hours ago - Takeda Pharmaceutical Company Limited (TAK) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 15 hours ago - Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO - CNBC
- 1 day ago - Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs - Benzinga
- 1 day ago - Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs - Benzinga
- 1 day ago - Earnings Scheduled For May 8, 2025 - Benzinga
- 1 day ago - Takeda Pharmaceutical Non-GAAP EPS of ¥491.00, revenue of ¥4581.6B; initiates FY25 outlook - Seeking Alpha
- 1 day ago - Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress - Business Wire
- 2 days ago - Takeda Pharmaceutical FY Earnings Preview - Seeking Alpha